Abstract
Stroke pathology involves multifactorial pro-death responses, including inflammation, oxidative stress, vascular dysfunction, and activation of necrotic and apoptotic pathways. The interruption of a single specific pathway in defined stroke model systems has not been sufficient to address the multifactorial nature of stroke-induced injuries in the human population. CD36 is a class B scavenger receptor that functions in regulating normal physiological and pathological functions. CD36 pathways are activated by several distinct ligands. Convergence of these pathways results in inflammatory responses and endothelial dysfunction, which may be an underlying cause of cardio- and cerebrovascular diseases. The current review describes receptor CD36-ligand interactions relevant to endothelial function and discusses how targeting CD36 may have therapeutic utility in stroke.
Keywords: CD36, stroke, angiogenesis, inflammation, endothelial dysfunction, pro-death responses, oxidative stress, vascular dysfunction, cerebrovascular diseases, scavenger receptor.
Current Pharmaceutical Design
Title:CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Volume: 18 Issue: 25
Author(s): Sunghee Cho
Affiliation:
Keywords: CD36, stroke, angiogenesis, inflammation, endothelial dysfunction, pro-death responses, oxidative stress, vascular dysfunction, cerebrovascular diseases, scavenger receptor.
Abstract: Stroke pathology involves multifactorial pro-death responses, including inflammation, oxidative stress, vascular dysfunction, and activation of necrotic and apoptotic pathways. The interruption of a single specific pathway in defined stroke model systems has not been sufficient to address the multifactorial nature of stroke-induced injuries in the human population. CD36 is a class B scavenger receptor that functions in regulating normal physiological and pathological functions. CD36 pathways are activated by several distinct ligands. Convergence of these pathways results in inflammatory responses and endothelial dysfunction, which may be an underlying cause of cardio- and cerebrovascular diseases. The current review describes receptor CD36-ligand interactions relevant to endothelial function and discusses how targeting CD36 may have therapeutic utility in stroke.
Export Options
About this article
Cite this article as:
Cho Sunghee, CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke, Current Pharmaceutical Design 2012; 18 (25) . https://dx.doi.org/10.2174/138161212802002760
DOI https://dx.doi.org/10.2174/138161212802002760 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemotherapeutic Options for Colorectal Cancer Patients with Cardiovascular Diseases.
Reviews on Recent Clinical Trials Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry Hyperhomocysteinemia and Sudden Cardiac Death: Potential Arrhythmogenic Mechanisms
Current Vascular Pharmacology The No-Reflow Phenomenon in the Coronary Circulation
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology The Modern Spectrum of Rhabdomyolysis: Drug Toxicity Revealed by Creatine Kinase Screening
Current Drug Safety Sodium Ion Transporters as New Therapeutic Targets in Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Thyroid Hormones and Cardiovascular System: From Bench to Bedside
Current Drug Therapy Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses Peak Treadmill Exercise Echocardiography
Reviews on Recent Clinical Trials Small Artery Remodeling in Obesity and Insulin Resistance
Current Vascular Pharmacology NLRP3 Is Involved in Ischemia/Reperfusion Injury
CNS & Neurological Disorders - Drug Targets Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry Subject Index to Volume 4
Current Drug Targets Vascular Injury During Elevated Glucose can be Mitigated by Erythropoietin and Wnt Signaling
Current Neurovascular Research Editorial (Hot Topic: Vascular Remodeling)
Current Vascular Pharmacology In Search for the Troponin of the Kidney
Current Medicinal Chemistry